Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Moleculin Biotech Inc (MBRX)

NASDAQ
Currency in USD
Disclaimer
4.350
-0.250(-5.43%)
Closed
After Hours
4.290-0.060(-1.379%)

MBRX Comments

Come on with that price target :o)
Nobody cares about today's news?
what are your tots on MBRX today?
Yikes
I'm grabbing a few more...
good dip!
Moleculin Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model
https://finance.yahoo.com/news/moleculin-announces-100-survival-achieved-123000065.html
hey guys who ever done from here go and buy (aumn)
reverse stock split?
yep *6
 now it makes sense haha
What does “reverse stock split” mean?
Damn RS, smh!
BioConnect 2021 Conference being held January 11-14 !!!
Buy now!!! Going 5$
You weren't wrong...
good 👍 stock to buy
Just own it, don't trade it.  It is under serious accumulation.
This company is for real.  Partnerships with the big boys and a pipeline that is impressive.  This could very well be the one that becomes a 100 bagger in a few years.  Buy it and don't even look.  Forget you own it.  Look when it hits $50.  Don't sell it there, but look.  Be able to say you bought it under $1.
The target is 3.33
https://www.marketwatch.com/press-release/moleculin-announces-successful-completion-of-pre-ind-meeting-with-the-fda-2020-09-09?mod=mw_quote_news
Movement
what?
what?
Any new info on this stock?
https://www.sciencedirect.com/science/article/pii/S155041312030365X?via%3Dihub
MBRX when will go up ?? Lets go baby
MBRX $1.25 @ 11:47 AM ET
Moleculin's WP1122 shows anti-SARS-CoV-2 effect in new lab tests Jul. 21, 2020 8:54 AM ET|About: Moleculin Biotech, Inc. (MBRX)|By: Vandana Singh, SA News Editor  Moleculin Biotech (NASDAQ:MBRX) rises ~35% PM in reaction to independent laboratory testing that confirms antiviral activity of WP1122 against coronavirus. The testing compared the therapeutic effects of 2-DG (the active ingredient in WP1122) alone with those of WP1122, a 2-DG prodrug. Additionally, the Company has also contracted with the independent lab to conduct preclinical toxicology testing, which is currently under way. Last month, the company announced repeat testing of candidate WP1122 confirmed its antiviral potential. WP1122 is a prodrug of 2-deoxy-D-glucose (2-DG). WP1122 is only metabolized once it is inside the cell, enabling much higher tissue and organ concentrations of 2-DG.
August 17th the quarterly reports come out
  Do your research, trust your instinct and you will know what to do.
holding it depends on whether you can afford to lose the money.. tbh.. i would get out with any profit you can.. because in the end.. if they don't deliver a vaccine.. its gonna drop.. and no ones buying..
 As i understand they are not developing a vaccine, but an antiviral treatment which might help infected people. A vaccine is far away, either at the end of this year or first quarter of next year. Until than, they need a treatment if the number of cases keep rising.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.